Search clinical trials for: GT90001 KN046

Total 53 results

Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

HER2 Positive Solid Tumor

China
Peking University Cancer Hospital & Institute

Not yet recruiting

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

HER2-positive Colorectal Cancer | HER2-positive Biliary Tract Cancer

China
Peking University

Not yet recruiting

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

HER2-positive Locally Advanced Resectable Gastric Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Advanced Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Alphamab (Australia) Co Pty Ltd.

Unknown

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Recruiting

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand
Suzhou Kintor Pharmaceutical Inc,

Completed

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

HCC | Metastatic Hepatocellular Carcinoma | Combinations of Drugs; Dependence

Taiwan
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Thymic Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

Squamous Non-small-cell Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
Peking University Cancer Hospital & Institute

Recruiting

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

The Efficacy and Safety of KN046 Combined With Axitinib

NSCLC

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Peking University

Completed

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

HER2-positive Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Changchun Intellicrown Pharmaceutical Co. LTD

Recruiting

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Advanced Solid Tumors

China
Michael Harrison
Shriners Hospitals for Children; Children's Mercy Hospital Kansas City

Completed

Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum (3MP)

Pectus Excavatum

United States
Maxinovel Pty., Ltd.

Not yet recruiting

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

Advanced / Metastatic Solid Tumors
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia
Celgene

Completed

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Peking University Cancer Hospital & Institute

Completed

The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

HCC

China
Suzhou Kintor Pharmaceutical Inc,

Active, not recruiting

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

HCC | Hepatocellular Carcinoma

United States
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Celgene

Terminated

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Liver Cirrhosis | Non-alcoholic Fatty Liver Disease

United States, Spain, Australia, Korea, Republic of, Canada, Germany, France, Japan, United Kingdom, Poland
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer

China
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College

Unknown

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Unknown

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Genticel
PPD

Terminated

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL

United States
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Rheumatic Diseases

China
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Terminated

Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

Rheumatoid Arthritis

China
Shanghai JMT-Bio Inc.

Recruiting

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Stomach Cancer

China

Search clinical trials for: GT90001 KN046

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations